<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.medscape.com/cx/rssfeeds/2700.xml</title><link>https://www.medscape.com/cx/rssfeeds/2700.xml</link><description>Individual feed output.</description><lastBuildDate>Wed, 19 Nov 2025 22:13:49 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>‘Lean Diabetes’ a Risk Factor for Dementia?</title><link>https://www.medscape.com/viewarticle/metabolic-stress-not-body-weight-may-explain-dementia-risk-2025a1000wb3?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture6.png</image_url><description>Clinicians may be overlooking ‘lean diabetes’ as a risk factor for dementia. Medscape Medical News</description><pubDate>Thu, 20 Nov 2025 02:30:58 GMT</pubDate></item><item><title>Second Anti-HER2 TKI Approved for NSCLC</title><link>https://www.medscape.com/viewarticle/second-anti-her2-tki-approved-nsclc-2025a1000wan?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture8.png</image_url><description>Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US market. Medscape Medical N...</description><pubDate>Wed, 19 Nov 2025 20:59:32 GMT</pubDate></item><item><title>Checkpoint Inhibitor Prices Dropped Marginally Over Decade</title><link>https://www.medscape.com/viewarticle/checkpoint-inhibitor-prices-dropped-marginally-over-decade-2025a1000wa8?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture8.png</image_url><description>A recent analysis reveals that monthly prices of checkpoint inhibitors decreased only a small amount over a decade. Medscape Medical News</description><pubDate>Wed, 19 Nov 2025 19:34:22 GMT</pubDate></item><item><title>Allergy Therapy Shortcut? Omalizumab Speeds OIT Start</title><link>https://www.medscape.com/viewarticle/allergy-therapy-shortcut-omalizumab-speeds-oit-start-2025a1000wa7?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture2.png</image_url><description>Children who received omalizumab pretreatment underwent less dose escalation in oral immunotherapy. Medscape Medical News</description><pubDate>Wed, 19 Nov 2025 19:29:09 GMT</pubDate></item><item><title>Despite Risks, Safety Warnings, Valproate Use On the Rise</title><link>https://www.medscape.com/viewarticle/despite-risks-safety-warnings-global-valproate-use-continues-2025a1000w9z?src=rss</link><image_url>https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png</image_url><description>Even as newer antiseizure drugs surge, global prescribing remains anchored to valproate, signaling slow adoption of safety recommendations. Medscape M...</description><pubDate>Wed, 19 Nov 2025 18:58:15 GMT</pubDate></item></channel></rss>